Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.
about
Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II studyEltrombopag in patients with chronic liver disease.Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.Pathophysiology and management of primary immune thrombocytopenia.Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease.The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia.The pharmacology and clinical application of thrombopoietin receptor agonists.Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia.Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection.Eltrombopag for treatment of thrombocytopenia-associated disorders.Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia.From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag.Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression.Eltrombopag: a review of its use in patients with severe aplastic anaemia.Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects.Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia.
P2860
Q33395943-A5A4D075-2C3E-4A17-85AA-6D19E67B5204Q33396286-2015D396-D35E-4271-A47E-700F4C5CEB2EQ33397968-C32217AD-5F9C-427C-9CEA-2C7B01C2900CQ33400203-7A011AC3-C57C-4E99-8BEA-4A6A320B9739Q33401211-2EA73463-08FE-4EC7-92BC-D14E32E68818Q33401660-5BC365E3-A8B7-4B6C-A828-81D6638D91CAQ33406181-8A1B405C-A5A1-4D56-A03A-E933F571E8D1Q33406932-29921FE9-36CA-4986-8D3B-C2479C837434Q33407942-6DBCC604-E6F3-4EE5-999C-91649C5D401EQ33409401-66A43DDE-3EB4-49D8-803B-891CE03031A9Q33410866-4D4B6D5E-DC74-4147-8965-EA651445E86DQ33414386-9DB5D8C8-0C33-433D-8BA2-3374178B9FB3Q33417700-40403F7B-6B6F-42E8-AB34-6B9189037823Q33419462-F3B6E2BD-9B47-455F-9D6F-0E486856FC0EQ33421634-0DE66DE4-ECDB-49AA-A62F-C6B58260FA33Q33424397-27ACE882-B491-49A6-9A0B-C6397490EF19Q33425805-F17586E9-E508-40E8-8C66-0F13806CF921Q33435986-6FE13AD7-0F71-42E9-A17C-58639692B7C0Q33441627-10AE274F-B2AD-49FD-9D6C-234939A3DA78Q35183649-755A9E3A-8231-40FB-87A6-96014A8D04C5Q37704712-C1CE3C93-A9CE-451C-8C2D-5030066873F4Q38363139-97C7263F-8F65-4B7D-A53E-164B646635E3Q39746668-BB7D07F7-396E-47C7-AFD6-BEA12834C200Q48305083-8F4E471D-FCE8-4D61-838C-22CD05F69978Q53809669-2758763E-B8B8-4275-B2F9-B53C3EB69D17
P2860
Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Population pharmacokinetics of ...... thic thrombocytopenic purpura.
@ast
Population pharmacokinetics of ...... thic thrombocytopenic purpura.
@en
type
label
Population pharmacokinetics of ...... thic thrombocytopenic purpura.
@ast
Population pharmacokinetics of ...... thic thrombocytopenic purpura.
@en
prefLabel
Population pharmacokinetics of ...... thic thrombocytopenic purpura.
@ast
Population pharmacokinetics of ...... thic thrombocytopenic purpura.
@en
P2093
P2860
P356
P1476
Population pharmacokinetics of ...... thic thrombocytopenic purpura.
@en
P2093
Daniele Ouellet
Daphne Williams
Ekaterina Gibiansky
Jianping Zhang
P2860
P304
P356
10.1177/0091270010375427
P577
2010-07-27T00:00:00Z